AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00088-07v1
51/8/3020    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaymakoglu, S.
Right arrow Articles by Okten, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaymakoglu, S.
Right arrow Articles by Okten, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2007, p. 3020-3022, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.00088-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pegylated Interferon Alfa-2b Monotherapy and Pegylated Interferon Alfa-2b plus Lamivudine Combination Therapy for Patients with Hepatitis B Virus E Antigen-Negative Chronic Hepatitis B{triangledown}

Sabahattin Kaymakoglu,1* Dilek Oguz,2 Gurden Gur,3 Selim Gurel,4 Ethem Tankurt,5 Galip Ersöz,6 Seren Ozenirler,7 Cem Kalayci,8 Sule Poturoglu,1 Yilmaz Cakaloglu,1 and Atilla Okten1

Department of Gastroenterohepatology, Istanbul University, Istanbul, Turkey,1 Department of Gastroenterology, Türkiye Yüksek Ihtisas Hospital, Ankara, Turkey,2 Department of Gastroenterology, Baskent University, Ankara, Turkey,3 Department of Gastroenterology, Uludag University, Bursa, Turkey,4 Department of Gastroenterology, Dokuz Eylül University, Izmir, Turkey,5 Department of Gastroenterology, Ege University, Izmir, Turkey,6 Department of Gastroenterology, Gazi University, Ankara, Turkey,7 Department of Gastroenterology, Marmara University, Istanbul, Turkey8

Received 20 January 2007/ Returned for modification 22 February 2007/ Accepted 3 May 2007

Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of <400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.

* Corresponding author. Mailing address: Istanbul University, Department of Gastroenterohepatology, Istanbul Medical Faculty, Capa, 34390, Istanbul, Turkey. Phone: 902124142000 (31140). Fax: 902126312257. E-mail: kaymakoglus{at}hotmail.com

{triangledown} Published ahead of print on 21 May 2007.

Antimicrobial Agents and Chemotherapy, August 2007, p. 3020-3022, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.00088-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.